Retatrutide vs Cagrilintide

Retatrutide vs Cagrilintide: Overview

Retatrutide and cagrilintide represent two distinct pharmacological strategies for addressing obesity and metabolic disease through multi-hormone modulation. Retatrutide (LY3437943), developed by Eli Lilly, is a triple-hormone receptor agonist that simultaneously engages GIP, GLP-1, and glucagon receptors. Cagrilintide, developed by Novo Nordisk, is a long-acting amylin receptor agonist designed to complement GLP-1 receptor agonist therapy — most notably as a component of the fixed-dose combination CagriSema (cagrilintide plus semaglutide 2.4 mg). The comparison of cagrilintide vs retatrutide illuminates how these fundamentally different multi-hormone approaches aim to maximise weight loss and metabolic improvement.

The rationale for comparing retatrutide vs cagrilintide stems from their shared positioning as next-generation therapies designed to exceed the weight loss efficacy of single-target GLP-1 receptor agonists. Research suggests that both approaches attempt to engage complementary satiety and metabolic pathways, but through entirely different receptor systems: retatrutide adds GIP and glucagon receptor agonism to GLP-1 signalling within a single molecule, while cagrilintide adds amylin pathway activation alongside GLP-1 agonism through either co-administration or fixed-dose combination.

Both compounds have generated phase 2 and phase 3 clinical data demonstrating substantial weight loss efficacy, and their development represents the leading edge of multi-hormone metabolic pharmacotherapy. Understanding the mechanistic and clinical differences between these approaches provides valuable context for the evolving treatment landscape.

Mechanism of Action

Retatrutide engages three distinct receptor systems simultaneously. GLP-1 receptor activation stimulates glucose-dependent insulin secretion, suppresses glucagon release from alpha cells, delays gastric emptying, and promotes satiety through hypothalamic signalling. GIP receptor activation enhances glucose-dependent insulin secretion through a complementary pathway and may influence adipose tissue metabolism and central appetite regulation. Glucagon receptor activation stimulates hepatic lipid oxidation, increases energy expenditure, and may enhance thermogenesis through brown and beige adipose tissue pathways. The integration of all three agonist activities within a single peptide molecule is designed to produce synergistic metabolic effects that exceed what any dual-agonist combination achieves.

Cagrilintide is a long-acting analog of amylin (islet amyloid polypeptide), a peptide hormone co-secreted with insulin from pancreatic beta cells. Amylin receptor activation produces several metabolic effects that are distinct from and complementary to GLP-1 receptor agonism: it slows gastric emptying through vagal afferent pathways, suppresses post-prandial glucagon secretion, and reduces food intake through area postrema signalling in the brainstem — a satiety pathway distinct from the hypothalamic pathways engaged by GLP-1. Cagrilintide’s mechanism thus targets a fundamentally different set of neural and hormonal circuits compared with retatrutide’s incretin and glucagon receptor-focused approach.

When cagrilintide is combined with semaglutide 2.4 mg as CagriSema, the resulting pharmacological profile engages both amylin and GLP-1 receptor pathways. This differs from retatrutide’s triple-agonist approach in that CagriSema represents a two-molecule combination targeting two receptor systems, while retatrutide is a single molecule targeting three receptor systems. The different satiety pathways engaged — brainstem amylin signalling versus incretin-based hypothalamic and glucagon-mediated metabolic effects — represent mechanistically distinct approaches to appetite and energy balance regulation.

Clinical Evidence

Retatrutide’s most significant clinical data comes from the phase 2 trial published by Jastreboff et al. in the New England Journal of Medicine in 2023, which enrolled 338 adults with obesity. This trial demonstrated dose-dependent weight reductions of up to 24.2% at 48 weeks with retatrutide 12 mg, representing the highest weight loss achieved with a pharmacological agent in controlled clinical trials at that time. A qualitative study of patients in this trial further characterised the perceived benefits of treatment. Retatrutide has advanced into the phase 3 TRIUMPH programme, though complete phase 3 results are not yet available.

Cagrilintide’s clinical development includes both standalone studies and combination investigations with semaglutide. A phase 2 trial by Lau et al. published in The Lancet evaluated once-weekly cagrilintide as a standalone agent in people with overweight and obesity, demonstrating dose-dependent body weight reductions of up to approximately 10.8% at 26 weeks. An earlier phase 1b study by Enebo et al. investigated the safety, tolerability, pharmacokinetics, and pharmacodynamics of cagrilintide co-administered with semaglutide 2.4 mg, establishing the feasibility and early efficacy signals for the combination approach.

The CagriSema combination has now completed phase 3 evaluation through the REDEFINE programme. Garvey et al. published the REDEFINE 1 results in the New England Journal of Medicine in 2025, demonstrating that CagriSema achieved body weight reductions of approximately 22.7% at 68 weeks in adults with overweight or obesity — results exceeding semaglutide 2.4 mg monotherapy. Davies et al. simultaneously published REDEFINE 2 results for CagriSema in adults with overweight or obesity and type 2 diabetes. Systematic reviews and meta-analyses by Ahmed et al. and Gadelmawla et al. have further analysed the comparative efficacy and safety of cagrilintide and CagriSema.

Efficacy Comparison

Comparing the weight loss efficacy of cagrilintide vs retatrutide requires distinguishing between cagrilintide as a standalone agent, CagriSema as a combination therapy, and retatrutide as a single-molecule triple agonist. As a standalone agent, cagrilintide achieved approximately 10.8% weight loss at 26 weeks in its phase 2 trial — clinically meaningful but substantially lower than retatrutide’s 24.2% at 48 weeks.

The more relevant comparison is between CagriSema and retatrutide, as both represent multi-hormone strategies designed to maximise weight loss. CagriSema achieved approximately 22.7% weight loss at 68 weeks in the REDEFINE 1 trial, while retatrutide achieved 24.2% at 48 weeks in its phase 2 trial. While cross-trial comparisons must be interpreted cautiously due to differences in trial design, duration, population, and dose-escalation protocols, these results suggest broadly comparable maximal weight loss efficacy between the two approaches, with retatrutide potentially achieving comparable or slightly greater weight reduction in a shorter timeframe.

Network meta-analyses incorporating both agents are emerging but limited by the different trial designs and populations studied. A comprehensive meta-analysis by Bailey et al. reviewing peptide-based therapies for obesity and type 2 diabetes noted the convergence of multiple multi-hormone approaches toward a plateau of approximately 20–25% body weight reduction, suggesting that this range may represent a pharmacological ceiling achievable through incretin and related hormone-based mechanisms.

Safety and Tolerability

Both retatrutide and cagrilintide share gastrointestinal adverse events as the most commonly reported side effects, though the specific patterns differ somewhat due to their distinct mechanisms. Retatrutide’s triple-agonist profile produces the nausea, vomiting, diarrhoea, and decreased appetite characteristic of GLP-1 receptor-active therapies, with gastrointestinal events reported in approximately 35–50% of participants in the phase 2 trial depending on dose level. Discontinuation rates due to adverse events were manageable.

Cagrilintide’s amylin agonist mechanism produces gastrointestinal effects that are mechanistically related but distinct in their neural pathway origin. Nausea is the most common adverse event, mediated through area postrema activation rather than the hypothalamic and peripheral mechanisms involved in GLP-1-mediated nausea. In the CagriSema phase 3 trials, the combination of amylin and GLP-1 agonism did not produce disproportionately higher gastrointestinal adverse event rates compared with semaglutide monotherapy, suggesting that the two mechanisms may not be additive in terms of tolerability burden. The systematic review and meta-analysis by Ahmed et al. confirmed a generally manageable safety profile for CagriSema.

Both agents carry class-related precautions. Retatrutide shares the GLP-1 class warnings regarding thyroid C-cell tumour risk (rodent data), pancreatitis, and gallbladder-related events. Cagrilintide’s amylin agonist mechanism introduces different theoretical considerations, including potential effects on gastric motility and mineral metabolism, though clinical data has not identified significant concerns in these areas. The long-acting amylin analog class has been reviewed by Bailey et al. in the context of emerging peptide therapies for obesity and type 2 diabetes.

Pharmacokinetics

Retatrutide is administered via once-weekly subcutaneous injection, with a half-life of approximately 6 days achieved through fatty acid-mediated albumin binding. The molecule is designed for balanced engagement of all three receptor targets throughout the dosing interval. Steady-state plasma concentrations are reached after approximately four to five weeks of weekly dosing, with dose-proportional pharmacokinetics across the evaluated dose range.

Cagrilintide is also administered via once-weekly subcutaneous injection. As a long-acting amylin analog, it has been engineered with structural modifications that extend its half-life to approximately 7 days, supporting the once-weekly dosing schedule. When administered as CagriSema, cagrilintide 2.4 mg is combined with semaglutide 2.4 mg in a single subcutaneous injection using a co-formulation approach. The pharmacokinetic profiles of both components have been characterised in the phase 1b study by Enebo et al., demonstrating that co-administration does not significantly alter the individual pharmacokinetic parameters of either component.

A key practical pharmacokinetic distinction is that retatrutide delivers triple-receptor agonism in a single injection, while CagriSema delivers dual-pathway activity (amylin + GLP-1) also in a single injection through co-formulation. Both approaches achieve once-weekly dosing convenience. The different molecular weights, albumin-binding properties, and receptor-binding profiles of these agents result in distinct tissue distribution patterns that may influence their tissue-level pharmacodynamic effects.

Current Research Status

Retatrutide is in phase 3 clinical development through the TRIUMPH programme, encompassing trials in obesity, type 2 diabetes, and metabolic-associated steatotic liver disease. Regulatory approval has not yet been obtained in any jurisdiction. The phase 2 results generated substantial interest based on the unprecedented weight loss observed, and phase 3 data will be critical for determining the compound’s therapeutic positioning. Additional studies examining retatrutide’s effects on liver histology and cardiovascular outcomes are anticipated.

Cagrilintide has been primarily developed as a component of CagriSema rather than as a standalone therapy. The REDEFINE programme has completed phase 3 evaluation, with results from REDEFINE 1 and REDEFINE 2 published in 2025. Regulatory submissions for CagriSema are underway, with potential market availability anticipated in the near term. The development of CagriSema represents a strategy of combining established therapeutic mechanisms (amylin and GLP-1) through a fixed-dose combination rather than engineering a single multi-agonist molecule. The long-term comparative positioning of these approaches — single-molecule multi-agonism versus combination therapy — remains an active area of clinical and commercial investigation.

Summary

The comparison of retatrutide and cagrilintide highlights two mechanistically distinct approaches to multi-hormone metabolic pharmacotherapy. Retatrutide’s single-molecule triple agonism (GIP/GLP-1/glucagon) achieved approximately 24% weight loss in phase 2, engaging incretin and glucagon pathways simultaneously. Cagrilintide, primarily developed as CagriSema (amylin + GLP-1), achieved approximately 22.7% weight loss in phase 3 through amylin-mediated brainstem satiety pathways complementing GLP-1 receptor agonism. Both approaches demonstrate robust glycaemic improvements and share manageable gastrointestinal tolerability profiles, though through mechanistically distinct pathways. The comparison is limited by the absence of direct head-to-head data and differences in trial design and maturity. CagriSema is further advanced in regulatory terms, while retatrutide is in phase 3 development.

References

• Jastreboff AM et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. PMID: 37366315
• Lau DCW et al. (2021). Once-weekly cagrilintide for weight management in people with overweight and obesity. The Lancet. PMID: 34798060
• Enebo LB et al. (2021). Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg. The Lancet. PMID: 33894838
• Garvey WT et al. (2025). Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. PMID: 40544433
• Davies MJ et al. (2025). Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. New England Journal of Medicine. PMID: 40544432
• Ahmed M et al. (2026). Efficacy and Safety of Cagrilintide and CagriSema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression. Diabetes, Obesity and Metabolism. PMID: 41834765
• Bailey CJ et al. (2026). Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes. Peptides. PMID: 41747885
• Madsbad S and Holst JJ. (2025). The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines. Expert Opinion on Investigational Drugs. PMID: 40022548